by Richard Daverman, PhD
November 7, 2012 -- Mindray Medical reported that its Q2 revenues rose 18% to $257 million, with non-GAAP net income up an equal 18% at $50 million. Unfortunately, those results were below analysts’ estimates. Also, a $10 million charge took EBITDA and net income lower than the prior year’s similar period. The charge derives from a pricing dispute with a supplier over costs for components of patient monitors sold in the US. More details....
Stock Symbol: (NYSE: MR)
